Evidence map›Paper›PMID 26367239›Full record

Trial reportBone marrow transplantation2016

Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study.

E Van Den Neste, N Schmitz, N Mounier, D Gill, D Linch, M Trneny, N Milpied, J Radford, N Ketterer, O Shpilberg and 8 more

Abstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Bone marrow transplantation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 140 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
140citing papers in PubMed, 4 pooled it
8.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

140 citing papers in PubMed, 4 syntheses or guidelines pooled it, 310 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Article

80 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 14 institutions in 9 countries.

E Van Den NesteCliniques Universitaires UCL Saint-Luc, Brussels, Belgium.
N SchmitzAsklepiosKlinik St Georg, AbteilungHämatologie und Stammzelltransplantation, Hamburg, Germany.
N MounierCHU de l'Archet, Nice, France.
D GillPrincess Alexandra Hospital, Woodville, SA, Australia.
D LinchUniversity College London, Cancer Institute, London, UK.
M TrnenyCharles Univ. General Hosp., Praha, Czech Republic.
N MilpiedHématologie Clinique et thérapie cellulaire, Hôpital Haut-Lévêque, Pessac, France.
J RadfordUniversity of Manchester, c/o Department of Medical Oncology, Christie Hospital NHS, Manchester, UK.
N KettererClinique Bois-Cerf, Lausanne, Switzerland.
O ShpilbergAssuta Medical Center, Tel-Aviv, Israel.
U DührsenUniversitätsklinikum Essen, KlinikfürHämatologie, Essen, Germany.
D MaSt Vincent's Hospital Sydney, Darlinghurst, NW, Australia.
J BrièreHemato-Oncologie Hôpital Hôpital Saint-Louis, Paris, France.
C ThieblemontHemato-Oncologie Hôpital Hôpital Saint-Louis, Paris, France.
G SallesHospices Civils de Lyon, Service d'Hématologie, Université de Lyon, Lyon, France.
C H MoskowitzMemorial Sloan Kettering Cancer Center, New York, NY, USA.
B GlassAsklepiosKlinik St Georg, AbteilungHämatologie und Stammzelltransplantation, Hamburg, Germany.
C GisselbrechtHemato-Oncologie Hôpital Hôpital Saint-Louis, Paris, France.
Hôpital Saint-Louis · FRAsklepios Klinik St. Georg · DEEssen University Hospital · DEAssuta Medical Center · ILCharles University · CZCliniques Universitaires Saint-Luc · BEHirslanden Clinique Bois-Cerf · CHHôpital Cardiologique du Haut-Lévêque · FRHôpital l'Archet · FRLondon Cancer · GBMemorial Sloan Kettering Cancer Center · USPrincess Alexandra Hospital · AUUniversité Claude Bernard Lyon 1 · FRUniversity of Manchester · GB

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Cancer Research UK 15556NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Salvage chemotherapy followed by autologous stem cell transplantation (ASCT) is the standard second-line treatment for relapsed and refractory diffuse large B-cell lymphoma (DLBCL). However, the strategy is less clear in patients who require third-line treatment. Updated outcomes of 203 patients who could not proceed to scheduled ASCT in the Collaborative Trial in Relapsed Aggressive Lymphoma (CORAL) are herein reviewed. In the intent-to-treat analysis, overall response rate to third-line chemotherapy was 39%, with 27% CR or CR unconfirmed, and 12% PR. Among the 203 patients, 64 (31.5%) were eventually transplanted (ASCT 56, allogeneic SCT 8). Median overall survival (OS) of the entire population was 4.4 months. OS was significantly improved in patients with lower tertiary International Prognostic Index (IPI), patients responding to third-line treatment and patients transplanted with a 1-year OS of 41.6% compared with 16.3% for the not transplanted (P<0.0001). In multivariate analysis, IPI at relapse (hazard ratio (HR) 2.409) and transplantation (HR 0.375) independently predicted OS. Third-line salvage chemotherapy can lead to response followed by transplantation and long-term survival in DLBCL patients. However, improvement of salvage efficacy is an urgent need with new drugs.

Indexed as

Stem Cell TransplantationAdolescentAdultAgedAutograftsDisease-Free SurvivalFemaleHumansLymphoma, Large B-Cell, DiffuseMaleMiddle AgedRecurrenceSalvage TherapySurvival Rate

Identifiers

PMID26367239
OpenAlexW2305142474

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.